Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

• Status: Unknown status
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Angiogenesis Inhibitors; Bevacizumab

Criteria

Inclusion Criteria:

• Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY

Exclusion Criteria:

• PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER